Abstract
Neurological disorders such as Alzheimer's disease, stroke, and brain cancers are difficult to treat with current drugs as their delivery efficacy to the brain is severely hampered by the presence of the blood–brain barrier (BBB). Drug delivery systems have been extensively explored in recent decades aiming to circumvent this barrier. In particular, polymeric nanoparticles have shown enormous potentials owing to their unique properties, such as high tunability, ease of synthesis, and control over drug release profile. However, careful analysis of their performance in effective drug transport across the BBB should be performed using clinically relevant testing models. In this review, polymeric nanoparticle systems for drug delivery to the central nervous system are discussed with an emphasis on the effects of particle size, shape, and surface modifications on BBB penetration. Moreover, the authors critically analyze the current in vitro and in vivo models used to evaluate BBB penetration efficacy, including the latest developments in the BBB-on-a-chip models. Finally, the challenges and future perspectives for the development of polymeric nanoparticles to combat neurological disorders are discussed.
Original language | English |
---|---|
Article number | 2003937 |
Number of pages | 32 |
Journal | Advanced Science |
Volume | 8 |
Issue number | 10 |
DOIs | |
Publication status | Published - 19 May 2021 |
Keywords
- blood–brain barrier
- drug delivery systems
- microfluidic chips
- neurological diseases
- polymeric nanoparticles
Equipment
-
Melbourne Centre for Nanofabrication
Sean Langelier (Manager)
Office of the Vice-Provost (Research and Research Infrastructure)Facility/equipment: Facility